Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14101567 | 0.94 | S1PR5 (0.35) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL14101563 | 0.92 | CYP1A2 (0.35) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL14101679 | 0.92 | ERBB2 (0.32) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL14101499 | 0.91 | ERBB2 (0.33) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL14101504 | 0.88 | CYP1A2 (0.33) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL14101498 | 0.87 | PDK2 (0.33) | — | |
| SCHEMBL25741492 | 0.87 | ALDH1A1 (0.36) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL26038188 | 0.84 | — | — | |
| SCHEMBL14101529 | 0.83 | S1PR5 (0.41) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL25741296 | 0.83 | CA12 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166594-A1 | BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080166594-A1 | BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166594-A1 | BENZOTHIOPHENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE MAKING USE OF THE SAME | CYBA, BPNT1, TYR | ERBB2 3074/4885CYP1A2 232/4885FYN 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.